Spelling suggestions: "subject:"ursodeoxycholic acid"" "subject:"ursodeocycholic acid""
1 |
Hepatic Copper Accumulation in Patients with Primary Biliary CirrhosisHAYASHI, HISAO, TAKIKAWA, TOSHIKUNI, ARAO, MOTOHIRO, KURIKI, JUNSUKE, KATO, SHOSHI, SAKAMOTO, NOBUO, YANO, MOTOYOSHI, YAGI, AKIRA, TAKESHIMA, HIROTOMO 03 1900 (has links)
No description available.
|
2 |
Evaluation of the United Kingdom-Primary Biliary Cholangitis and Global Primary Biliary Cholangitis Group Prognostic Models for Primary Biliary Cholangitis Patients Treated with Ursodeoxycholic Acid in the U.S. PopulationAlomari, Mohammad, Covut, Fahrettin, Al Momani, Laith, Chadalavada, Pravallika, Hitawala, Asif, Young, Mark F., Romero-Marrero, Carlos 01 April 2020 (has links)
JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley and Sons Australia, Ltd. Background and Aim: The United Kingdom-primary biliary cholangitis (UK-PBC) and global primary biliary cholangitis group (GLOBE) prognostic models have been recently developed to predict long-term outcomes in primary biliary cholangitis (PBC). However, these predictive scores have not yet been well evaluated in the U.S. population. Methods: We retrospectively reviewed newly diagnosed PBC patients at the Cleveland Clinic between November 1998 and February 2017. Adverse events were defined as liver transplantation, liver-related mortality, and all-cause mortality. Transplant-free survival (TFS) was estimated using the Kaplan–Meier method. Predictive performances of all prognostic models were evaluated using the C-statistic. Results: We identified 352 patients who used ursodeoxycholic acid therapy. Of them, 311 (88.4%) only had PBC, while 41 (11.6%) were diagnosed with PBC-autoimmune hepatitis overlap. A total of 22 (6%), 47 (13%), and 55 (16%) patients had adverse events within 5, 10, and 15 years after diagnosis, respectively. In patients with PBC only, the C-statistic in predicting 15-year adverse events was 0.75 per GLOBE compared to 0.74 per UK-PBC (P = 0.94), 0.73 per Rotterdam (P = 0.44), 0.66 per Barcelona (P = 0.004), 0.65 per Paris 1 (P = 0.005), 0.62 per Paris 2 (P < 0.0001), 0.60 per Toronto (P < 0.0001), and 0.60 per Mayo (P < 0.0001) scores. Median follow-up was 9.2 years. Ten-year TFS for patients who had optimal versus suboptimal treatment response was 92 versus 74% per Paris 1 (P < 0.0001), 95 versus 79% per Paris 2 (P = 0.0002), 93 versus 65% per Barcelona (P < 0.0001), and 96 versus 68% per Rotterdam (P < 0.0001) risk scores, respectively. Conclusion: In our cohort of PBC patients, the UK-PBC and GLOBE scores were both accurate and reasonably valid prognostic models in the U.S. population.
|
3 |
Efeito do ácido ursodesoxicólico e o papel da mucosa no desenvolvimento de dismotilidade esofagiana: estudo experimental com cobaias / Effects of ursodeoxycholic acid and the role of mucosa in esophageal dysmotility. An experimental studyRocha, Marcelo Eustáquio Siqueira [UNIFESP] 26 May 2010 (has links) (PDF)
Made available in DSpace on 2015-07-22T20:49:55Z (GMT). No. of bitstreams: 0
Previous issue date: 2010-05-26 / Objetivo: Determinar o efeito do ácido ursodesoxicólico e o papel da mucosa no aparecimento de alterações motoras, na musculatura esofagiana de cobaias. Métodos: Trabalho experimental realizado com 18 cobaias albinas do sexo masculino pesando entre 200 e 250g. Os animais foram distribuídos em 03 grupos, sendo assim constituídos: Grupo (A)- 06 animais formaram o grupo experimental – Esôfago com mucosa, Grupo (B)- 06 animais formaram o grupo experimental – Esôfago sem mucosa e Grupo (C)- 06 animais formaram o grupo controle. Os animais foram sacrificados e o esôfago distal foi removido. Após identificação da transição epitelial escamo-colunar, foi realizada a secção ao nível da mesma desprezando-se a câmara gástrica. Os espécimes de esôfago foram encaminhados para prova de avaliação contrátil, utilizando-se câmaras de perfusão de órgãos e um sistema de aquisição de dados com o programa KITCAD 8. Os espécimes foram mantidos em solução salina oxigenada por 01 hora, com estiramento de 01 grama a fim de readquirirem sua tensão basal e foram estimulados com 40mM de KCl. Após a verificação da manutenção contrátil e avaliação da amplitude contrátil inicial, os fragmentos foram banhados na solução de 100 mM de ácido ursodesoxicólico, nos grupos A e B, e em solução salina fisiológica, no grupo C, por 01 hora, e, então, novamente estimulados com 40mM de KCl, e realizados cinco estímulos com intervalo de cinco minutos para o registro da amplitude contrátil. Resultados: A média da amplitude de contração antes da incubação (pré) variou entre os grupos (p=0,006) com médias de 1,319(A), 0,306(B) e 1,795(C). Após a incubação (pós), a média da amplitude de contração foi de 0,709 , 0,278 e 1,353 para os grupos A, B e C, respectivamente. Antes da incubação, não houve diferença na amplitude de contração entre os grupos A e C (p=0,633) e houve diferença entre os grupos A e B (p=0,039) e B e C (p=0,048). Após a incubação, quando comparamos as diferenças das médias dentro dos grupos nos momentos pré e pós, encontramos apenas diferenças no grupo A (p=0,030). Conclusões: A exposição esofagiana ao ácido ursodexosicólico, componente da bile, induz a uma diminuição da amplitude de contração esofagiana. A mucosa esofagiana desempenha importante papel na motilidade esofagiana. / Background and Aims: Esophageal motor abnormalities are frequently found in patients with gastroesophageal reflux disease. The role of bile in reflux-induced dysmotility is still elusive. Furthermore, it is questionable weather mucosal or muscular stimulation leads to motor modification. The aims of this study were: (a) analyze the effect of bile infusion in the amplitude of esophageal contractions and (b) analyze the effect of mucosal vs muscular stimulation. Methods: 18 guinea-pig esophagi were isolated and its contractility assessed with force transducers. Three groups were studied. In group A (n= 6) the entire esophagus was used and incubated in 100 ìML ursodeocycholic acid for 2 hours. In group B (n=6) the mucosal layer was removed and the muscular layer incubated in 100 ìML ursodeocycholic acid for 1 hours. In group C (n=6) (control group) the entire esophagus was used and incubated in saline solution. In all groups, five sequential contractions spaced by 1 minute were measured before and after incubation. Contractions were recorded after KCl 40 mM stimulation. Results: Contractions before incubation did differed among groups (p= 0,006) and averaged 1,319(A),0,306(B) and 1,795(C). After incubation amplitude of contraction was 0,709 , 0,278 and 1,353 for groups A, B and C respectively. Before incubation there were no diferrences between groups A and C (p=0,633) there was difference between groups A and B (p=0,039) and B and C (p=0,048). After incubation when we compare average within groups (before and after) there was difference only in group A (p=0,030). Conclusion: Our results show that bile exposure may induce ineffective esophageal motility and the mucosa seems to take an important role in esophageal motility. Disclosure Statement: No author has commercial associations that might create a conflict of interest. No competing financial interests exist. / TEDE / BV UNIFESP: Teses e dissertações
|
4 |
Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing CholangitisWilde, Anne-Christin Beatrice, Greverath, Lena Marie, Steinhagen, Lara Marleen, de Chamorro, Nina Wald, Leicht, Elise, Fischer, Janett, Herta, Toni, Berg, Thomas, Preuss, Beate, Klein, Reinhild, Tacke, Frank, Müller, Tobias 02 June 2023 (has links)
Background: Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) constitute rare chronic inflammatory biliary diseases which likely comprise genetic, environmental and autoimmune factors. Specific inhibitory (auto-) antibodies against the muscarinic acetylcholine receptor type 3 (mAChR3 auto-ab) may contribute to the pathogenesis of chronic biliary inflammation by modulating mAChR3− mediated signaling. Aims: The aim of this study was to analyze the prevalence and relevance of inhibitory mAChR3 auto-ab (mAChR3inh+ auto-ab) in a large cohort of PBC patients from two independent tertiary centers in Berlin and Leipzig in comparison to a large PSC cohort. Baseline parameters and response rates to standard treatment with ursodeoxycholic acid (UDCA) were characterized with respect to the individual mAChR3 auto-ab status. Methods: In total, the study population comprised 437 PBC patients, 187 PSC patients and 80 healthy controls. Clinical and laboratory baseline characteristics were retrieved from medical records. The response to ursodeoxycholic acid (UDCA) therapy after 12 months of treatment was available in 176 PBC and 45 PSC patients. Results: The prevalence of mAChR3inh+ auto-ab was significantly higher among PBC patients (11.2%, 49/437; p = 0.008 vs. healthy controls) and PSC patients (33.6%, 63/187; p < 0.0001 vs. healthy controls) compared to healthy controls (2.5%, 2/80), respectively. PBC patients with mAChR3inh+ auto-ab exhibited significantly higher levels of alkaline phosphatase (ALP) and bilirubin, which constitute established parameters for PBC risk stratification. Moreover, mAChR3inh+ PBC patients tended to show decreased response rates to UDCA therapy compared to PBC patients without mAChR3inh+ auto-ab (mAChR3− PBC). In contrast, PSC patients with mAChR3inh+ auto-ab showed no significant differences in laboratory findings compared to mAChR3 auto-ab negative (mAChR3−) PSC patients. Conclusion: MAChR3inh+ auto-ab might be involved in the pathogenesis and treatment response of chronic biliary inflammation in patients with PBC but not in patients with PSC.
|
5 |
Uticaj sintetske i prirodne žučne kiseline na oksidativni stres i apoptozu hepatocita / Influence of synthetic and natural bile acid on oxidative stress and apoptosis in hepatocytesAndrejić Višnjić Bojana 03 March 2016 (has links)
<p>Žučne kiseline (ŽK) su strukturno raznoliki molekuli, koji pored uloge koju ostvaruju putem žuči, deluju i kao signalni molekuli i ostvaruju kako endokrina tako i parakrina dejstva. Činjenica da je do sada u terapijske svrhe primenjivana samo ursodeoksiholna kiselina (UDK), posledica je brojnih ograničenja u mogućnosti primene ostalih prirodnih ŽK, i ističe potrebu za otkrivanjem novih sintetskih ŽK i liganda. Cilj istraživanja bio je ispitivanje sintetske 12-monoketoholne kiseline (MK) i prirodne UDK u modelu holestaze i aloksanom izazvanog dijabetesa. Ispitivanja su vršena na pacovima soja Wistar. Analizirana je telesna masa, glikemija, pokazatelji jetrene funkcije (AST; ALT, γ-GT, ukupni i direktni bilirubin), a iz homogenate jetre određen je intenzitet lipidne peroksidacije i aktivnost antioksidativnih enzima (CAT, GSH-Px, GSH-R, GSH-ST). Isečci tkiva jetre su histološki obrađeni i bojeni hematoksilin-eozin metodom i histohemijskim metodama (retikulin, Mallory, Periodic Acid Schiff- Alcian Blue (PAS/AB)). Imunohistohemijski je ispitana proliferacija hepatocita (Ki-67), markeri apoptoze (p53, Bcl-2, Bcl-X, Bax) i ekspresija nuklearnog farnesoid X receptora (FXR). Rezultati istraživanja pokazuju da ispitivane ŽK pomažu očuvanje telesne mase u holestazi i dijabetesu, i značajno snižavaju glikemiju kod dijabetičnih jedinki. Parametri jetrene funkcije u holestazi i dijabetesu su regulisani primenom MK i UDK. Obe ŽK u značajnoj meri smanjuju intenzitet lipidne peroksidacije i pojačavaju enzimsku antioksidativnu odbranu hepatocita u holestazi i dijabetesu. Ekspresija markera apoptoze nije značajno promenjena izazvanjem modela holestaze i dijabetesa, kao ni primenom ispitivanih ŽK. Nasuprot tome, izazivanje holestaze i dijabetesa značajno smanjuje proliferaciju hepatocita, dok primena MK i UDK poništava ovaj efekat i značajno povećava proliferaciju hepatocita. Hiperglikemija u aloksanskom dijabetesu nije dovela do pojačane ekspresije FXR. Izazivanje holestaze kod zdravih i dijabetičnih životinja dovelo je do porasta ekspresije FXR, koja je redukovana primenom MK i UDK. Na osnovu dobijenih rezultata može se zaključiti da sintetska 12-monoketoholna kiselina pokazuje slična hipoglikemijska, hepatoprotektivna i antioksidativna dejstva kao i prirodna ursodeoksiholna kiselina.</p> / <p>Bile acids (BAs) are structurally diverse molecules, which have theroles in the digestive system, which are exercised through the bile. Beside those, BAs act as a signaling molecules and achieve endocrine and paracrine effects. In addition to its own metabolism, bile acids modulate the metabolism of lipids and glucose. The fact that so far only ursodeoxycholic acid (UDC) is used for therapeutic purposes, speak clearly about of numerous limitations on the application of other natural BAs, and highlights the need to develop new synthetic Bas and ligands. The aim of this study was to investigate the influence of synthetic 12-monoketocholic acid (MC) and natural bila acid UDC in the model of cholestasis and alloxan-induced diabetes. Tests were performed on male Wistar rats. We analyzed the body mass, glucose, liver function tests (AST, ALT, γ-GT, total and direct bilirubin). Using liver tissue homogenates we determined intensity of lipid peroxidation (by concentration of malondilaldehyde) and the activity of antioxidant enzymes (CAT, GSH-Px, GSH -R, GSH-ST). Liver tissue were histologically processed and stained with hematoxylin-eosin method and histochemical methods (reticulin, Mallory, Periodic Acid Schiff- Alcian Blue (PAS / AB)). Imunohistochemical examination included hepatocyte proliferation (Ki-67), markers of apoptosis (p53, Bcl-2, Bcl-X, Bax), and expression of the nuclear farnesoid X receptor (FXR). Results of the research show that MC prevented decrease in body mass during cholestasis and diabetes, and significantly reduced glycemia in diabetic animals. The liver function tests in cholestasis and diabetes are normalised by MC and UDC aplication. Both BAs significantly reduce lipid peroxidation and enhance enzymatic antioxidant defense of hepatocytes in cholestasis and diabetes. The expression of markers of apoptosis was not significantly changed in models of cholestasis and diabetes, as well as the application of the tested BAs. In contrast, in cholestasis and diabetes model, the proliferation of hepatocytes was significantly reduced, while the use of MC and UDC reversed this effect and significantly increased the proliferation of hepatocytes. Hyperglycemia in alloxan-induced diabetes did not lead to overexpression of FXR. Induction of cholestasis in healthy and diabetic animals resulted in an increase in the expression of FXR, which is reduced by using the MK and the UDC. Based on these results we can conclude that a synthetic 12-monoketocholic acid shows similar hypoglycemic, hepatoprotective and antioxidant effects as natural ursodeoxycholic acid.</p>
|
6 |
Cibler le système digestif pour protéger le foie : évaluation de l’efficacité prophylactique et thérapeutique de traitements de l’encéphalopathie hépatique dans un modèle murin de cholestase hépatique par ligature de la voie biliairePetrazzo, Grégory 10 1900 (has links)
Introduction. L’encéphalopathie hépatique (HE) est une complication commune mais sévère des insuffisances hépatiques. La physiopathologie de l’HE provient essentiellement de l’ammoniac dérivé du métabolisme des bactéries intestinales. Le traitement standard pour les patients qui subissent des épisodes manifestes d’HE est le lactulose mais son observance est faible du fait d’effets secondaires inconfortables. La rifaximine est un candidat potentiel mais il n’y a pas de données issues d’essais cliniques suffisamment robustes pour supporter sa seule utilisation. Les traitements anti-fibrotiques sont une autre piste de traitement dans le sens où s’il est possible de prévenir l’avancement de la défaillance hépatique il est alors possible de diminuer la probabilité et la sévérité des épisodes. Deux études indépendantes ont été réalisées dans un modèle de ligature de la voie biliaire, la première étude pour évaluer l’efficacité de traitements thérapeutiques de l’HE (lactulose et rifaximine) utilisés seuls ou en combinaison pour réduire le taux d’ammoniac et améliorer le statut de l’HE; et la seconde étude, pour évaluer des traitements utilisés individuellement pour prévenir l’établissement de la fibrose (acide obéticholique, rapamycine, pirfénidone, acide ursodésoxycholique).
Matériel et méthodes. Les deux projets utilisent un modèle murin de ligature de la voie biliaire. Pour l’évaluation de la rifaximine, trois semaines après la chirurgie, les animaux sont séparés en cinq groupes en fonction du traitement reçu quotidiennement et du modèle : SHAM-VEH, pour les animaux ayant subi un simulacre de chirurgie de ligature de la voie biliaire (SHAM) et traité par le véhicule (VEH); BDL-VEH, pour les animaux ayant subi la chirurgie de ligature de la voie biliaire et traité par le véhicule; BDL-RIF, pour les animaux traités par la rifaximine (RIF); BDL-LAC, pour les animaux traités par le lactulose (LAC); BDL-LAC+RIF, pour les animaux traités par le lactulose et la rifaximin (LAC+RIF). Pour l’évaluation des composés anti-fibrotiques, une semaine après la chirurgie, les animaux sont séparés en six groupes en fonction du traitement reçu quotidiennement et du modèle : SHAM-VEH; BDL-VEH; BDL-OCA pour les animaux traités par l’obéticholique acide (OCA); BDL-RPM, pour les animaux traités par la rapamycine (RPM); BDL-UDCA, pour les animaux traités par l’acide ursodésoxycholique (UDCA); BDL-PFN pour les animaux traités par la pirfenidone (PFN). Les animaux sont alors évalués au cours du modèle pour leur survie, leur consommation de nourriture et leur poids. Les paramètres biochimiques de la fonction hépatiques sont évalués en fin de modèle. Plus particulièrement, le projet sur les composés anti-fibrotiques comprend une analyse plus approfondie de la fibrose par histologie avec établissement du score MÉTAVIR et par mesure du contenu hépatique en hydroxyproline. Le projet rifaximine comprend des analyses comportementales pour évaluer l’HE mais également une mesure de l’œdème cérébral.
Résultats. Pour le projet rifaximine, aucun des deux composés testés (i.e. rifaximin et lactulose) seuls ou combinaison n’ont pas eu d’effets bénéfiques globaux en termes de survie, de croissance, de consommation de nourriture, de tests comportementaux, d’œdème cérébral, de paramètres biochimiques incluant l’ammoniac. Aucun des traitements pris séparément ou en combinaison n’a montré d’efficacité pour le traitement de l’HE. Pour le projet des composés anti-fibrotiques, certains composés ont entrainé une mortalité plus élevée. Aucune différence entre les traitements ne fut observée en termes de croissance, de consommation de nourriture, de paramètres biochimiques, d’histologie et de contenu en hydroxyproline.
Conclusions. Globalement, l’étude sur la rifaximine ne présente pas de résultats suffisamment concluants pour recommander l’utilisation de la rifaximine en remplacement ou en concomitance avec le lactulose. L’étude sur les composés anti-fibrotiques ne permet pas de mettre en évidence un composé capable de limiter la progression de la fibrose. / Introduction. Hepatic encephalopathy (HE) is a major but common complication of
liver failures diseases. The physiopathology of HE mainly involves intestinal bacteria
metabolism derived ammonia. The golden standard for patients who experience overt episodes
of HE is lactulose but its observance is poor due to uncomfortable side effects. On the other
hand, Rifaximin is a potent candidate but there is a lack of relevant data from clinical trials to
support its sole use. Antifibrotic drugs are another category of treatment that can be useful in
the setting of HE since it can prevent the onset of cirrhosis and thus of the liver failure, this can
decrease the appearance and severity of the episodes. The aim of this study is to evaluate in a
murine model of bile duct ligation the efficiency of therapeutic treatments (lactulose and
rifaximin) alone or in combination to decrease blood ammonia and ameliorate HE status; and of
prophylactic treatments (obeticholic acid, rapamycin, pirfenidone, ursodeoxycholic acid)
individually to prevent the onset of fibrosis.
Materials and methods. The two projects used a murine model of bile duct ligation.
For the evaluation of the efficiency of rifaximin, three weeks after surgery, the animals were
sorted into five groups according to the treatment they received daily and according to the model
: SHAM-VEH, for animals that underwent a mock surgery (SHAM) and were treated with
vehicle (VEH); BDL-VEH, for animals that underwent a bile duct ligation surgery (BDL) and
were treated with vehicle; BDL-RIF, for animals that were treated with rifaximin (RIF); BDLLAC,
for animals that were treated with lactulose (LAC); BDL-LAC+RIF for animals that were
treated with lactulose and rifaximin (LAC+RIF);. For the evaluation of the effect of antifibrotic
drugs, one week after surgery, the animals were sorted into six groups according to the treatment
they received daily and according to the model : SHAM-VEH, BDL-VEH, BDL-OCA for
animals that were treated with obeticholic acid (OCA); BDL-RPM, for animals that were treated
with rapamycine (RPM); BDL-UDCA, for animals that were treated with ursodeoxycholic acid
(UDCA); BDL-PFN, for animals that were treated with pirfenidone (PFN). All animals were
evaluated during the model for survival, food consumption and growth. The biological
parameters of the liver function were evaluated at the end of the model. More specifically, this
project includes a deeper analysis on fibrosis through histological analysis with establishment of the METAVIR score and measure of the content on hydroxyproline. The rifaximin project
includes behavioural analysis to evaluate the HE status and measurement of cerebral edema.
Results. Concerning the rifaximin project, no difference can be established between the
treatments in term of survival, growth, food consumption, behavioural tests, cerebral edema,
biochemistry parameters including ammonia. No treatment, taken alone or in combination,
showed efficacy to treat HE. Concerning the antifibrotic drug study, some compounds have
shown an increase in mortality, although no difference can be observed on growth, food
consumption, biochemistry parameters, histology or hydroxyproline content.
Conclusions. Overall, the study on rifaximin does not present strong and conclusive
results on the sole use of rifaximin. According to the study on the antifibrotic drugs, no
compounds show evidence of prevention of the onset of the fibrosis.
|
7 |
L'effet de l'âge gestationnel sur l'incidence, l'étiologie, le traitement et le pronostic de la cholestase néonataleEl Raichani, Nadine 08 1900 (has links)
Cadre conceptuel et problématique : La cholestase hépatique est une pathologie à large éventail d’étiologies, affectant fréquemment les nouveau-nés. Un diagnostic approprié est essentiel pour la prise en charge clinique, le choix des traitements et l’amélioration du pronostic. Alors que les prématurés ont un risque accru de développement de la cholestase, les algorithmes de traitement ne proposent qu’une prise en charge unique, quel que soit l’âge gestationnel (AG) du patient.
Objectif : Déterminer si le profil clinique, la prise en charge et le pronostic de la cholestase néonatale diffèrent selon l’AG.
Méthodologie : Une étude de cohorte rétrospective de nouveau-nés atteints de cholestase et admis en néonatologie au CHU Sainte Justine entre janvier 2014 et décembre 2017 a été menée. La cholestase était définie par au moins deux valeurs consécutives de bilirubine conjuguée ≥ 34 μmol/L. La cohorte a été stratifiée en deux groupes d’AG : les extrêmes et les grands prématurés (< 32 semaines AG) et les prématurés modérés ou tardifs et naissances à terme (≥ 32 semaines AG).
Résultats : 125 nouveau-nés sur 3 277 ont développé une cholestase. L’incidence globale était de 4% ; cette incidence était 5 fois plus élevée chez les nouveau-nés < 32 semaines d’AG comparativement aux ≥ 32 semaines d’AG. La cholestase était associée à une nutrition parentérale chez 91% des patients avec AG < 32 semaines et seulement 40% des patients avec AG ≥ 32 semaines (p < 0,01). Alors que l'acide ursodésoxycholique était plus prescrit aux nouveau-nés ≥ 32 semaines AG, les émulsions lipidiques à base d'huile de poisson étaient plus administrées aux nouveau-nés < 32 semaines AG, parmi les patients recevant une nutrition parentérale.
Conclusion : La cholestase néonatale est associée à deux profils cliniques différents, basés sur l'AG. Nous recommandons que les tests diagnostics et la prise en charge clinique de la cholestase soient adaptés à l'AG. Une nouvelle approche pour l'évaluation d'un nourrisson atteint d'hyperbilirubinémie conjuguée est proposée. / Background and Aims: Cholestasis is a frequent neonatal disease that has a wide range of etiologies. Appropriate diagnosis is essential to clinical management, treatment choices and improvement of outcomes. Most references discuss neonatal cholestasis as one entity. The goal of this study was to determine if the clinical profile, management and outcome of cholestasis differ according to gestational age (GA).
Methods: Medical records of infants with cholestasis in the division of neonatology at CHU Sainte Justine, between January 2014 and December 2017, were retrospectively reviewed. Cholestasis was defined as two or more consecutive conjugated bilirubin values ≥ 34μmol/L. The cohort was stratified into two groups: extremely to very preterm (< 32 weeks GA) and moderate to late preterm and term (≥ 32 weeks GA).
Results: 125 of 3,277 patients developed cholestasis. Overall incidence of cholestasis was 4%. Incidence was 5 times higher in neonates < 32 weeks GA compared to neonates ≥ 32 weeks GA. Cholestasis was associated with parenteral nutrition in 91% of patients with GA < 32 weeks and 40% of patients with GA ≥ 32 weeks (p < 0.01). While ursodiol treatment was prescribed more to cholestatic neonates ≥ 32 weeks GA, fish oil lipid was administered more to neonates < 32 weeks GA, among patients receiving parenteral nutrition.
Conclusions: Neonatal cholestasis was associated with two different clinical profiles based on GA. We recommend diagnostic tests and clinical management of neonatal cholestasis be adapted to GA. A GA-based approach to the evaluation of an infant with conjugated hyperbilirubinemia is proposed.
|
Page generated in 0.0809 seconds